Core Insights - BioVie Inc. has appointed Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors, enhancing its leadership in neuroscience drug development and corporate finance [1][2][3] Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and long COVID, as well as advanced liver disease [5] - The company's lead drug candidate, bezisterim, targets neuroinflammation and insulin resistance, which are key factors in Alzheimer's and Parkinson's diseases, as well as neurological symptoms of long COVID [5] Leadership Expertise - Dr. Amy S. Chappell has over 25 years of experience in clinical neuroscience, having played a significant role in the development and FDA approval of multiple CNS therapies during her tenure at Eli Lilly & Co. [2] - Kameel D. Farag has a strong background in biotech and global finance, with experience in scaling companies and securing significant financing, including over $150 million at Aspen Neuroscience [3] Clinical Development Progress - BioVie is advancing bezisterim through Phase 2 trials for early Parkinson's disease and long COVID, while also planning further clinical development for Alzheimer's disease and ascites programs [2][4] - The company recently presented promising data on bezisterim's potential to slow or reverse biological aging and neurodegeneration at a major conference [4] Regulatory Status - BioVie’s orphan drug candidate BIV201, which is under FDA Fast Track status, is being evaluated for its effectiveness in reducing further decompensation in patients with liver cirrhosis and ascites [5]